April 26th 2021
Brian I. Rini, MD, discusses the mechanism of action of tivozanib in relapsed/refractory renal cell carcinoma.
November 6th 2020
Brian I. Rini, MD, discusses choosing between combinations of dual immunotherapy and immunotherapy/VEGF TKIs in metastatic renal cell carcinoma.
September 24th 2019
Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses challenges with biomarkers in renal cell carcinoma (RCC).
May 23rd 2019
Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses managing the toxicity of pembrolizumab plus axitinib in patients with metastatic renal cell carcinoma.
April 24th 2019
Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the combination of pembrolizumab plus axitinib in the treatment of patients with metastatic renal cell carcinoma.
March 2nd 2019
Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the potential for tivozanib in patients with advanced renal cell carcinoma.
November 7th 2018
Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the molecular characteristics of patients with renal cell carcinoma (RCC) enrolled on the IMmotion151 study.
July 3rd 2018
Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the tolerability of atezolizumab (Tecentriq) plus bevacizumab (Avastin) in renal cell carcinoma.
June 20th 2018
Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses atezolizumab (Tecentriq) plus bevacizumab (Avastin) in renal cell carcinoma.
June 12th 2018
Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses findings from the IMmotion151 trial in renal cell carcinoma.
August 4th 2017
Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the efficacy of pembrolizumab (Keytruda) and axitinib (Inlyta) combined in patients with renal cell carcinoma (RCC).
July 21st 2017
Brian I. Rini, MD, professor of Medicine, Cleveland Clinic, discusses sequencing of immunotherapy combinations for patients with renal cell carcinoma (RCC).
July 6th 2017
Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the potential of immunotherapy as an adjuvant treatment for patients with renal cell carcinoma (RCC).
June 14th 2017
Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses a phase I study of pembrolizumab (Keytruda) plus axitinib (Inlyta) in patients with renal cell carcinoma (RCC).
October 19th 2015
Brian Rini, MD, associate professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, discusses a phase Il study that examined axitinib as a second-line therapy for metastatic renal cell carcinoma.
October 13th 2014
Rini, who is a professor at the Cleveland Clinic Lerner College of Medicine in addition to holding several posts at the Case Comprehensive Cancer Center, discussed broad issues in antiangiogenic research in this interview with OncologyLive.
May 7th 2014
Brian Rini, MD, associate professor, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, discusses the role of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma (RCC).
February 14th 2014
Brian Rini, MD, associate professor, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, discusses professional practice gaps and barriers to optimal care of renal cell carcinoma (RCC).
November 17th 2011
Dr. Brian I. Rini from the Cleveland Clinic Discusses the VEGF Targeted Agent Axitinib
July 22nd 2011
Dr. Brian I. Rini from the Taussig Cancer Institute Describes Hypertension as a Biomarker in RCC